Login to Your Account

Ablynx shares fall as Abbvie passes on vobarilizumab in RA

By Cormac Sheridan
Staff Writer

Thursday, October 20, 2016

DUBLIN – Shares in Ablynx NV dropped 18 percent Thursday morning on news that Abbvie Inc. decided not to trigger an option to take forward vobarilizumab in rheumatoid arthritis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription